Be Bio Announces New Preclinical Data Demonstrating its Novel Engineered B Cell Medicine (BCM), BE-101, Produces Active and Sustained Levels of Factor IX for the Treatment of Hemophilia B?

SAN DIEGO–(BUSINESS WIRE)– #ASH2023–Be Bio presents new study showing active and sustained levels of Factor IX and announces plans to advance BE 101 as lead program for hemophilia B.
Click here to view original post